par Guiot, J.;Parzibut, G.;Weber, Thierry;Davin, Laurent;Dulgheru, Raluca Elena R.;Lancellotti, Patrizio;Louis, R.;Vachiery, Jean-Luc 
Référence RMLG. Revue médicale de Liège, 74, 3, page (139-145)
Publication Publié, 2019-02-01
Référence RMLG. Revue médicale de Liège, 74, 3, page (139-145)
Publication Publié, 2019-02-01
Article révisé par les pairs
| Résumé : | Pulmonary arterial hypertension (PAH) is a rare vascular lung disease with a complex etiopathogeny characterized by an increased pulmonary arterial pressure of 25 mmHg or above assessed by right heart catheterization. The diagnosis is difficult due to the atypical presentation with shortness of breath requiring a sequential approach bringing at the end the clinician to perform a right heart catheterization. Nowadays, several therapies have proven to be efficient for treating PAH. Recently, international recommendations have moved to an initial combination therapy reducing the overall morbi-mortality of the patients. Therefore, early therapy appears to be a priority in PAH underlying the need for increasing the global knowledge around PAH. |
